Clinical Trial Update: Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ambrisentan, an endothelin receptor antagonist, for hepatorenal syndrome; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ascites
• Hepatorenal Syndrome
• Kidney Injury
• Liver Cirrhosis

Drugs mentioned

• LETAIRIS (ambrisentan)

Snippet

Sponsor: Noorik Biopharmaceuticals AG | Conditions: Hepatorenal Syndrome, Liver Cirrhosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING